

## SUPPLEMENTARY MATERIAL

## Polymeric nanofibre scaffold for the delivery of a transforming growth factor- $\beta$ inhibitor


*Vipul Agarwal,<sup>a</sup> Fiona M. Wood,<sup>b, c</sup> Mark Fear,<sup>c</sup> and K. Swaminathan Iyer<sup>a, \*</sup>*

<sup>a</sup> School of Chemistry and Biochemistry, The University of Western Australia, Crawley, Western Australia, Australia.


<sup>b</sup> Burns Service Western Australia, Department of Health, Perth, Western Australia, Australia

<sup>c</sup> Burn Injury Research Unit, School of Surgery, The University of Western Australia, Crawley, Western Australia, Australia


\*Corresponding author: Email: [swaminatha.iyer@uwa.edu.au](mailto:swaminatha.iyer@uwa.edu.au)



**Figure S1:** Cell proliferation assay showing cell growth over the period of 72 h post incubation with the free drug (PXS64). Data presented as Mean  $\pm$  SD (n = 3). Significance was set at \* p < 0.05 using bonferroni post-hoc analysis in one way ANOVA.



**Figure S2:** Cell viability assay showing the percentage of live cells in the culture post incubation with the free drug (PXS64). Data presented as average  $\pm$  SEM (n=4).



**Figure S3:** Collagen I gene expression analysis showing the percentage change in gene expression as compared to non-treated negative control (column 1). HDF cells incubated on both scaffolds and plastic tissue culture plate both in presence and absence of TGFβ<sub>1</sub> and release media. Data presented as average ± standard error mean (n = 3). Significance was set at \* p < 0.05 using bonferroni post-hoc test in one-way ANOVA analysis.